These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29778260)

  • 1. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
    Norton BL; Akiyama MJ; Zamor PJ; Litwin AH
    Infect Dis Clin North Am; 2018 Jun; 32(2):347-370. PubMed ID: 29778260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
    Meemken L; Hanhoff N; Tseng A; Christensen S; Gillessen A
    Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.
    Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J
    Clin Infect Dis; 2020 May; 70(11):2369-2376. PubMed ID: 31300820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
    Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
    Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
    Scherz N; Bruggmann P; Brunner N
    Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
    Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
    BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
    J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
    Barocas JA
    Clin Infect Dis; 2021 Apr; 72(8):1401-1403. PubMed ID: 32166311
    [No Abstract]   [Full Text] [Related]  

  • 15. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
    Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
    Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.
    Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B
    Clin Infect Dis; 2021 Jul; 73(1):e107-e118. PubMed ID: 32447375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
    Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
    Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
    J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.